IP Library › Granted Patent US 7,311,924
Granted Patent B2
US 7,311,924 · App. 10/407,864 · Granted Dec 25, 2007

Compositions and methods for treating cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,311,924
App. No.
10/407,864
Granted
Dec 25, 2007
Kind
B2
Abstract

This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.

Claims (14)

1. A method of treating a solid tumor in a mammal, comprising administering to said mammal a pharmaceutical composition comprising liposome-encapsulated vinorelbine, wherein the said solid tumor is selected from the group consisting of lung cancer, breast cancer, colon cancer, prostate cancer and renal cancer.

2. The method of claim 1 , wherein the pharmaceutical composition is administered to said mammal every seven days.

3. The method of claim 2 , wherein said pharmaceutical composition is administered to said mammal for at least three weeks.

4. The method of claim 2 , wherein the therapeutic index of the pharmaceutical composition is greater than the therapeutic index of free vinorelbine.

5. The method of claim 4 , wherein the therapeutic index of the pharmaceutical composition is at least 1.4-fold greater than the therapeutic index of free vinorelbine.

6. The method of claim 4 , wherein the therapeutic index of the pharmaceutical composition is at least 2-fold greater than the therapeutic index of free vinorelbine.

7. The method of claim 4 , wherein the therapeutic index of the pharmaceutical composition is at least 2.4-fold greater than the therapeutic index of free vinorelbine.

8. The method of claim 4 , wherein the therapeutic index of the pharmaceutical composition is at least 3.6-fold greater than the therapeutic index of free vinorelbine.

9. The method of claim 1 , wherein the liposome comprises sphingomyelin and cholesterol.

10. The method of claim 9 , wherein the ratio of sphingomyelin to cholesterol is between 75/25 and 50/50 (mol % sphingomyelin/mol % cholesterol).

11. The method of claim 10 , wherein the ration of sphingomyelin to cholesterol is approximately 55:45 (mol % sphingomyelin/mol % cholesterol).

12. The method of claim 1 , wherein the ratio of vinorelbine to lipid is 0.001-0.5:1 (w/w).

13. The method of claim 12 , wherein the ratio of vinorelbine to lipid is at least 0.1:1 (w/w).

14. The method of claim 13 , wherein the ratio of vinorelbine to lipid is 0.1-0.3:1 (w/w).

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2014
From: BANK OF MERICA, N.A.
To: SPECTRUM PHARMACEUTICALS, INC.
Reel/Frame 031996/0565 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 23, 2013
From: TALON THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 031263/0934 →
CHANGE OF NAME Recorded Aug 26, 2011
From: HANA BIOSCIENCES, INC.
To: TALON THERAPEUTICS , INC.
Reel/Frame 026815/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2007
From: INEX PHARMACEUTICALS CORPORATION
To: HANA BIOSCIENCES, INC.
Reel/Frame 019993/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2003
From: SARRIS, ANDREAS H.; CABANILLAS, FERNANDO
To: UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER, THE
Reel/Frame 014209/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2003
From: LOGAN, PATRICIA M.; BURGE, CLIVE T.R.; GOLDIE, JAMES H.; WEBB, MURRAY S.; MADDEN, THOMAS D.; SEMPLE, SEAN C.; AHKONG, QUET F.; KLIMUK, SANDRA K.
To: INEX PHARMACEUTICALS CORPORATION
Reel/Frame 014209/0623 →